New inhalation-optimized itraconazole nanoparticle-based dry powders for the treatment of invasive pulmonary aspergillosis

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 5475-5489

  Duret, Christophe ^a   Wauthoz, Nathalie ^a   Sebti, Thami ^b   Vanderbist, Francis ^b   Amighi, Karim ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b SMB Laboratoires   (Belgium)

Author keywords

Aspergillosis; Homogenization; Inhalation; Saturation; Solubility; Spray drying

Indexed keywords

ITRACONAZOLE; MANNITOL; TAUROCHOLIC ACID; TOCOFERSOLAN;

AQUEOUS SOLUTION; ARTICLE; CHEMICAL COMPOSITION; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STRUCTURE; DRY POWDER; FLOW KINETICS; INHALATION; LUNG ASPERGILLOSIS; NANOPHARMACEUTICS; PARTICLE SIZE; PHYSICAL CHEMISTRY; SCANNING ELECTRON MICROSCOPY; SPRAY DRYING;

ADMINISTRATION, INHALATION; ANTIFUNGAL AGENTS; CAPSULES; DESICCATION; DRUG COMPOUNDING; INVASIVE PULMONARY ASPERGILLOSIS; ITRACONAZOLE; MATERIALS TESTING; NANOPARTICLES; POWDERS; SOLUBILITY; TREATMENT OUTCOME;

EID: 84870316205     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S34091     Document Type: Article

References (49)

1. Hope WW. Invasion of the alveolar-capillary barrier by Aspergillus spp.: therapeutic and diagnostic implications for immunocompromised patients with invasive pulmonary aspergillosis. Med Mycol. 2009;47 Suppl 1:S291-S298.
2. Pfaller MA, Diekema DJ. Epidemiology of invasive mycoses in North America. Crit Rev Microbiol. 2010;36:1-53.
3. Le J, Schiller DS. Aerosolized delivery of antifungal agents. Curr Fungal Infect Rep. 2010;4:96-102.
4. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 2003;56: 600-612.
5. Duret C, Wauthoz N, Sebti T, Vanderbist F, Amighi K. Solid dispersions of itraconazole for inhalation with enhanced dissolution, solubility and dispersion properties. Int J Pharm. 2012;428:103-113.
6. Mobley C, Hochhaus G. Methods used to assess pulmonary deposition and absorption of drugs. Drug Discov Today. 2001;6:367-375.
7. Müller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev. 2001;47:3-19.
8. Rabinow BE. Nanosuspensions in drug delivery. Nat Rev Drug Discov. 2004;3:785-796.
9. Sung JC, Pulliam BL, Edwards DA. Nanoparticles for drug delivery to the lungs. Trends Biotechnol. 2007;25:563-570.
10. Sham JO, Zhang Y, Finlay WH, Roa WH, Lobenberg R. Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung. Int J Pharm. 2004;269:457-467.
11. Yang W, Peters JI, Williams RO 3rd. Inhaled nanoparticles-a current review. Int J Pharm. 2008;356:239-247.
12. Weers JG. Dispersible powders for inhalation applications. Innov Pharm Technol. 2000;1:111-116.
13. El Gendy N, Berkland C. Combination chemotherapeutic dry powder aerosols via controlled nanoparticle agglomeration. Pharm Res. 2009;26:1752-1763.
14. El Gendy N, Gorman EM, Munson EJ, Berkland C. Budesonide nanoparticle agglomerates as dry powder aerosols with rapid dissolution. J Pharm Sci. 2009;98:2731-2746.
15. Pilcer G, Vanderbist F, Amighi K. Preparation and characterization of spray-dried tobramycin powders containing nanoparticles for pulmonary delivery. Int J Pharm. 2009;365:162-169.
16. Salem H, Abdelrahim M, Eid KA, Sharaf M. Nanosized rods agglomerates as a new approach for formulation of a dry powder inhaler. Int J Nanomedicine. 2011;6:311-320.
17. Daviskas E, Anderson SD, Jaques A, Charlton B. Inhaled mannitol improves the hydration and surface properties of sputum in patients with cystic fibrosis. Chest. 2010;137:861-868.
18. Hinds WC. Aerosol Technology: Properties, Behavior, and Measurement of Airborne Particles. 2nd ed. New York: Wiley; 1999: 42-47.
19. Son YJ, McConville JT. Development of a standardized dissolution test method for inhaled pharmaceutical formulations. Int J Pharm. 2009;382:15-22.
20. Pham S, Wiedmann TS. Note: dissolution of aerosol particles of budesonide in Survanta, a model lung surfactant. J Pharm Sci. 2001;90:98-104.
21. Van Eerdenbrugh B, Van den MG, Augustijns P. Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. Int J Pharm. 2008;364:64-75.
22. Hecq J, Deleers M, Fanara D, Vranckx H, Amighi K. Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine. Int J Pharm. 2005;299:167-177.
23. Keck CM, Muller RH. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm. 2006;62:3-16.
24. Van Eerdenbrugh B, Van den Mooter G, Augustijns P. Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. Int J Pharm. 2008;364: 64-75.
25. Pilcer G, Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm. 2010;392:1-19.
26. Wang B, Zhang W, Zheng W, Mujumdar AS, Huang L. Progress in drying technology for nanomaterials. Drying Technol. 2004;23: 1-18.
27. Van Eerdenbrugh B, Froyen L, Van Humbeeck J, Martens JA, Augustijns P, Van den Mooter G. Drying of crystalline drug nanosuspensions-the importance of surface hydrophobicity on dissolution behavior upon redispersion. Eur J Pharm Sci. 2008;35:127-135.
28. Chaubal MV, Popescu C. Conversion of nanosuspensions into dry powders by spray drying: a case study. Pharm Res. 2008;25: 2302-2308.
29. Chan HK, Gonda I. Development of a systematic theory of suspension inhalation aerosols. 2. Aggregates of monodisperse particles nebulized in polydisperse droplets. Int J Pharm. 1988;41:147-157.
30. Binks BP. Particles as surfactant-similarities and differences. Curr Opin Colloid Interface Sci. 2002;7:21-41.
31. Majumder M, Rendall C, Eukel A, Wang J, Behabtu Natnael, Pint C, Liu T, Orbaek A, Mirri F, Nam J,. Barron A, Hauge R, Schmidt H, Pasquali M, Overcoming the "Coffee-Stain" Effect by Compositional Marangoni-Flow-Assisted Drop-Drying, J Phys chem; 2012; 116:6536-6542.
32. Tsapis N, Bennett D, Jackson B, Weitz D, Edwards DA. Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc Natl Acad Sci U S A. 2002;99:12001-12005.
33. Stroock AD, Dertinger SK, Ajdari A, Mezic I, Stone HA, Whitesides GM. Chaotic mixer for microchannels. Science. 2002;295: 647-651.
34. Hao J, Li SK. Mechanistic study of electroosmotic transport across hydrated nail plates: effects of pH and ionic strength. J Pharm Sci. 2008;97:5186-5197.
35. Duret C, Wauthoz N, Sebti T, Vanderbist F, Amighi K. New respirable and fast dissolving itraconazole dry powder composition for the treatment of invasive pulmonary aspergillosis. Pharm Res. 2012, 29(10):2845-59.
36. Morris G, Kokki MH, Anderson K, Richardson MD. Sampling of Aspergillus spores in air. J Hosp Infect. 2000;44:81-92.
37. Eduard W. Fungal spores: a critical review of the toxicological and epidemiological evidence as a basis for occupational exposure limit setting. Crit Rev Toxicol. 2009;39:799-864.
38. Pasqualotto AC. Differences in pathogenicity and clinical syndromes due to Aspergillus fumigatus and Aspergillus flavus. Med Mycol. 2009;47 Suppl 1:S261-S270.
39. Weiler C, Egen M, Trunk M, Langguth P. Force control and powder dispersibility of spray dried particles for inhalation. J Pharm Sci. 2010;99:303-316.
40. Soubani AO, Chandrasekar PH. The clinical spectrum of pulmonary aspergillosis. Chest. 2002;121:1988-1999.
41. Chew NY, Tang P, Chan HK, Raper JA. How much particle surface corrugation is sufficient to improve aerosol performance of powders? Pharm Res. 2005;22:148-152.
42. Byron PR, Peart J, Staniforth JN. Aerosol electrostatics. I: Properties of fine powders before and after aerosolization by dry powder inhalers. Pharm Res. 1997;14:698-705.
43. Yang W, Johnston KP, Williams RO 3rd. Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats. Eur J Pharm Biopharm. 2010;75: 33-41.
44. Denning DW, Hope WW. Therapy for fungal diseases: opportunities and priorities. Trends Microbiol. 2010;18:195-204.
45. Zhang J, Wu L, Chan HK, Watanabe W. Formation, characterization, and fate of inhaled drug nanoparticles. Adv Drug Deliv Rev. 2011;63: 441-455.
46. Peters K, Kruss B, Becker R, Müller RH. Pharmaceutical nanosuspensions for medicament administration as systems with increased saturation solubility and rate of solution. United States patent US005858410A. January 12, 1999.
47. Müller RH, Peters K. Nanosuspensions for the formulation of poorly water soluble drugs. I. Preparation by a size reduction technique. Int J Pharm. 1998;160:229-237.
48. Lee RW, Shaw JM, McShane J, Wood RW. Particle size reduction. In: Liu R, editor. Water-Insoluble Drug Formulation. Denver: Interpharm Press; 2000:455-492.
49. Kayaert P, Anne M, Van den MG. Bead layering as a process to stabilize nanosuspensions: influence of drug hydrophobicity on nanocrystal reagglomeration following in-vitro release from sugar beads. J Pharm Pharmacol. 2011;63:1446-1453.